Get the Stockscreener App
1.45
1.40%
0.02
After Hours:
1.46
0.01
+0.69%
Pds Biotechnology Corporation stock is traded at $1.45, with a volume of 120.35K.
It is up +1.40% in the last 24 hours and down -26.02% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.43
Open:
$1.46
24h Volume:
120.35K
Relative Volume:
0.30
Market Cap:
$54.24M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.2393
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+2.84%
1M Performance:
-26.02%
6M Performance:
-63.84%
1Y Performance:
-64.55%
1-Day Range:
$1.41
$1.52
1-Week Range:
$1.302
$1.52
52-Week Range:
$1.302
$6.68
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.45 | 54.24M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Inspirion Wealth Advisors LLC Sells 270,862 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - MarketBeat
PDSB stock touches 52-week low at $1.51 amid market challenges - Investing.com Nigeria
Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha
Geode Capital Management LLC Acquires 37,142 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Ball Co. (NYSE:BALL) Shares Sold by GAMMA Investing LLC - Defense World
PDS Planning Inc Has $23.21 Million Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Meet Gauzy and Research Frontiers at CES This Week to See the Latest in SPD-SmartGlass Products and Technology - Quantisnow
State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp Announces Pricing Of Public Offering Of About $12 mln Shares - Reuters
PDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC Wainwright - MarketBeat
DBV stock rallies post-market on FDA Viaskin update (NASDAQ:DBVT) - Seeking Alpha
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PDS Biotech Grants Stock Options to New Clinical Employee Under Inducement Plan - StockTitan
PDSBPDS Biotechnology Corporation Latest Stock News & Market Updates - StockTitan
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET - The Manila Times
PDS Biotech Announces Expert Panel on HPV16 Cancer Treatment Phase 3 Trial - StockTitan
A share offer that's hard to refuse - Investors Chronicle
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors - Newsfile
Research Analysts Issue Forecasts for PDSB FY2024 Earnings - Defense World
FY2024 EPS Estimate for PDS Biotechnology Lowered by Analyst - MarketBeat
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - MSN
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC - OncLive
PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PDS Biotechnology Corporation (PDSB) Quarterly 10-Q Report - Quartzy
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks
Earnings call: PDS Biotech reports progress in HPV cancer trials By Investing.com - Investing.com Canada
Earnings call: PDS Biotech reports progress in HPV cancer trials - Investing.com
PDSB stock touches 52-week low at $2.21 amid market challenges - Investing.com India
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications - MarketWatch
PDS Biotechnology Corporation Provides Clinical Programs Update - Marketscreener.com
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results - The Manila Times
PDS Biotech Reports $10.7M Q3 Loss, Streamlines Phase 3 Trial Design | PDSB Stock News - StockTitan
PDS Biotechnology (PDSB) to Release Earnings on Thursday - Defense World
PDS Biotechnology (NASDAQ:PDSB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
PDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):